SUMATRIPTAN SUCCINATE tablet, film coated

Quốc gia: Hoa Kỳ

Ngôn ngữ: Tiếng Anh

Nguồn: NLM (National Library of Medicine)

Thành phần hoạt chất:

SUMATRIPTAN SUCCINATE (UNII: J8BDZ68989) (SUMATRIPTAN - UNII:8R78F6L9VO)

Sẵn có từ:

Carilion Materials Management

INN (Tên quốc tế):

SUMATRIPTAN SUCCINATE

Thành phần:

SUMATRIPTAN 25 mg

Tuyến hành chính:

ORAL

Loại thuốc theo toa:

PRESCRIPTION DRUG

Chỉ dẫn điều trị:

Sumatriptan succinate tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: - Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with sumatriptan succinate tablets, reconsider the diagnosis of migraine before sumatriptan succinate tablets are administered to treat any subsequent attacks. - Sumatriptan succinate tablets are not indicated for the prevention of migraine attacks. - Safety and effectiveness of sumatriptan succinate tablets have not been established for cluster headache. Sumatriptan succinate tablets are contraindicated in patients with: - Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions ( )] 5.1 - W

Tóm tắt sản phẩm:

NDC:68151-1658-4 in a CUP of 1 TABLET, FILM COATEDS

Tình trạng ủy quyền:

Abbreviated New Drug Application

Đặc tính sản phẩm

SUMATRIPTAN SUCCINATE - SUMATRIPTAN SUCCINATE TABLET, FILM COATED
CARILION MATERIALS MANAGEMENT
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
SUMATRIPTAN SUCCINATE TABLETS SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR SUMATRIPTAN
SUCCINATE TABLETS. SUMATRIPTAN SUCCINATE
TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1992
INDICATIONS AND USAGE
Sumatriptan succinate tablets are a serotonin (5-HT ) receptor agonist
(triptan) indicated for acute treatment of migraine
with or without aura in adults. ( )
1
Limitations of Use:
Use only if a clear diagnosis of migraine headache has been
established. ( ) 1
Not indicated for the prophylactic therapy of migraine attacks. ( ) 1
Not indicated for the treatment of cluster headache. ( ) 1
DOSAGE AND ADMINISTRATION
Single dose of 25 mg, 50 mg, or 100 mg tablet.( ) 2.1
A second dose should only be considered if some response to the first
dose was observed. Separate doses by at least 2
hours. ( ) 2.1
Maximum dose in a 24-hour period: 200 mg. ( ) 2.1
Maximum single dose should not exceed 50 mg in patients with mild to
moderate hepatic impairment. ( ) 2.2
DOSAGE FORMS AND STRENGTHS
Tablets: 25 mg, 50 mg, and 100 mg ( ) 3
CONTRAINDICATIONS
History of coronary artery disease or coronary artery vasospasm ( ) 4
Wolff-Parkinson-White syndrome or other cardiac accessory conduction
pathway disorders ( ) 4
History of stroke, transient ischemic attack, or hemiplegic or basilar
migraine ( ) 4
Peripheral vascular disease ( ) 4
Ischemic bowel disease ( ) Uncontrolled hypertension ( ) 44
Recent (within 24 hours) use of another 5-HT agonist (e.g., another
triptan) or of an ergotamine-containing medication. (
)
4
Concurrent or recent (past 2 weeks) use of monoamine oxidase-A
inhibitor. ( ) 4
Hypersensitivity to sumatriptan succinate tablets (angioedema and
anaphylaxis seen). ( ) 4
Severe hepatic impairment. ( ) 4
WARNINGS AND PRECAUTIONS
Myocardial ischemia/infarction and Prinzmetal’s angina: Perform
cardiac evalua